Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(29%)
Results Posted
50%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph early_phase_1
1
14%
Ph phase_1
1
14%
Ph phase_2
5
71%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
Active, not recruiting2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 25 (71.4%)

Trials by Status

completed229%
terminated114%
active_not_recruiting229%
unknown229%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_2

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

NCT05999812
active_not_recruitingearly_phase_1

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

NCT05482451
completedphase_2

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

NCT03572387
unknownphase_2

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

NCT05175508
unknownphase_2

A Study of ATRA in the Treatment of ITP

NCT04618328
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05999812Phase 2

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Active Not Recruiting
NCT05482451Early Phase 1

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Active Not Recruiting
NCT03572387Phase 2

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Completed
NCT05175508Phase 2

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Unknown
NCT04618328Phase 2

A Study of ATRA in the Treatment of ITP

Unknown
NCT03259516Phase 1

Nivolumab With Chemotherapy in Refractory MDS

Terminated
NCT00000621Phase 2

Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7